Hypoxic Ischemic Encephalopathy Clinical Trial
— TTM36-IHCAOfficial title:
Targeted Temperature Management at 36℃ After In-Hospital Cardiac Arrest Trial(TTM36-IHCA Trial): An Investigator-Initiated, Single-Center, Randomized, Controlled, Assessor-Blinded, Pilot Clinical Trial
The purpose of this study is to determine whether targeted temperature management at
36.0˚C(TTM-36) in patients who remain unconscious after resuscitation from in-hospital
cardiac arrest(IHCA) will reduce death and disability compared with fever control. For this
purpose, the current pilot study will be undertaken to establish the feasibility, safety,
and surrogate outcomes of hypoxic-ischemic brain injury in 60 patients who remain
unconscious after resuscitation from IHCA.
Eligible patients will be randomly assigned in a 2:1 ratio to either TTM-36(n=40) or
conventional treatment group(n=20). Randomization will be performed with stratification
according to initial rhythm (shockable vs. non-shockable).
Status | Recruiting |
Enrollment | 60 |
Est. completion date | April 2018 |
Est. primary completion date | April 2018 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Age 18-80 years - In-hospital cardiac arrest requiring chest compression for > 2 minutes - Sustained restoration of spontaneous circulation(ROSC) for > 20 minutes after cardiopulmonary resuscitation(CPR) - Unresponsive state(lack of meaningful response to verbal commands) for > 20 minutes after sustained ROSC - Informed consents from a patient's family member Exclusion Criteria: - Unavailable TTM within 2 hours after ROSC - CPR duration > 30 minutes - Unwitnessed arrest with initial rhythm asystole - Under or planned for extracorporeal membrane oxygenation(ECMO) - Initial body temperature < 33 °C - Preexisting terminal illness with life expectancy <6 months - Pre-admission CPC score of 3-5 - Pre-admission mRS score 4-6 - Unresponsive(stupor or coma) before cardiac arrest - Suspected or confirmed cause of cardiac arrest is diseases of the central nervous system, such as stroke, brain tumor, or amyotrophic lateral sclerosis - Any condition in which direct skin surface cooling would be contraindicated, such as large burns, unhealed surgical wounds, decubitus ulcers, cellulitis, or other conditions with disrupted skin integrity - Active massive bleeding - Major surgery within last 48 hours - Cardiothoracic surgery within 14 days - Planned surgery within next 72 hours after ROSC - Enrolled in other clinical trials - Pregnant women - Do-not-resuscitate(DNR) state - Patients whose family or treating physicians refuse to join this study |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Asan Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Asan Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Safety of the targeted temperature management at 36.0?(TTM-36) | Safety will be assessed by the composite measurement below everyday during the first 7 days after cardiac arrest. Cardiac arrest after randomization Arrhythmia(ventricular fibrillation, ventricular tachycardia, atrial fibrillation, atrial flutter, tachycardia >130/min lasting more than 1 hour, and bradycardia <40/min lasting more than 1 hour) Pneumonia(pulmonary infiltration on the chest radiography and 2 or more of fever, leukocytosis, and purulent tracheobronchial secretions) Septic shock(sepsis-induced hypotension persisting despite adequate fluid resuscitation) Culture-proven infection Major bleeding(bleeding requiring more than 2 units of packed red blood cell over 2 hours, bleeding causing fatality, and symptomatic bleeding in critical organs) Shivering(the Bedside Shivering Assessment Scale 2-3) |
up to day 7 | Yes |
Other | Feasibility | 2.5 subjects per month can be recruited At least 50% of all eligible patients can be recruited No more than 10% of all recruited subjects cross over from one modality to the other Complete follow-up in at least 90% of all recruited subjects |
up to day 180 | No |
Primary | Combination of death and poor neurological function defined as a Cerebral Performance Category (CPC) score 3 to 5 at 180 days | Efficacy of targeted temperature management at 36.0?(TTM-36) will be assessed by using Cerebral Performance Category(CPC) score. CPC score is the surrogate outcome for hypoxic-ischemic brain injury. | day 180 | Yes |
Secondary | The CPC score 3 to 5 at day 7 and at day 30 | day 7, day 30 | Yes | |
Secondary | The highest levels of serum neuron specific enolase(NSE) during the first 5 days | up to day 5 | Yes | |
Secondary | Unfavorable Electroencephalography(EEG) patterns | Generalized suppression(=20 µV) Burst-suppression with generalized epileptiform activity Generalized periodic epileptiform discharges on a flat background No EEG reactivity Electrographical seizures Electrographical status epilepticus |
day 0, day 4 | Yes |
Secondary | Assessment of magnetic resonance imaging(MRI) at day 4 | Total magnetic resonance imaging(MRI) scores The percentage of brain volume with Afferent Diffusion Coefficient(ADC) values < 650 x 10^-6mm^2/sec The percentage of brain volume with ADC values < 450 x 10^-6mm^2/sec Number of cerebral microbleeds |
day 4 | Yes |
Secondary | Modified Rankin Scale(mRS) score 4 to 6 at day 30 and at Day 180 | day 30, day 180 | Yes | |
Secondary | All-cause mortality at day 30, at Day 180 | up to day 180 | Yes | |
Secondary | Myoclonic or tonic-clonic seizures or status epilepticus(SE) | up to day 7 | Yes | |
Secondary | Neurological status estimated by the Seoul Neurosychological Screeninig Battery (SNSB) 2nd ed. | Attention: Digit span (forward), digit span (backward) Language & related function: Spontaneous speech, comprehension, repetition, reading, writing, finger naming, body part identification, right-left orientation, calculation; BNT (Boston Naming Test) Visuospatial: RCFT (Rey Complex Figure Test) copy score Memory: SVLT (Seoul Verbal Learning Test), RCFT (immediate recall, delayed recall, recognition) Frontal & executive function: COWAT (Controlled Oral Word Association Test), CWST (Color Word Stroop Test), DSC (Digit Symbol Coding), TMT (Trail making test) General cognitive index: MMSE (Mini Mental State Examination), CDR (Clinical Dementia Rating), GDS (Global Deterioration Scale) Activities of daily living (ADL): Barthel index |
day 180 | Yes |
Secondary | Other neurological evaluations | Depression: BDI (Beck Depression Inventory) Quality of life: SF-36 (Short-Form 36-item Health Survey) Activities of daily life: S-IADL (Seoul-Instrumental Activities of Daily Living) Psychiatric symptoms: NPI (Neuropsychiatric Inventory) Cognition: IQCODE (Informant Questionnaire on Cognitive Decline in the Elderly) Parkinsonism: UPDRS (Unified Parkinson's Disease Rating Scale) Ataxia: ICARS (International Cooperative Ataxia Rating Scale) |
day 180 | Yes |
Secondary | Assessment of follow-up MRI | Resting state functional MRI: Connectivity strength, proportional increase of connectivity strength on resting state Diffusion tensor imaging: Global mean diffusivity, gray matter mean diffusivity, white matter mean diffusivity , mean fractional anisotropy, proportional increase of white matter global fractional anisotropy, proportional increase of white matter global mean diffusivity High resolution T1-weighted imaging for MRI volumetric: Mean volume of the brain, mean volume of the gray matter of the brain, mean volume of the white matter of the brain, proportional increase of mean volume of the brain, proportional increase of mean volume of the gray matter, proportional increase of mean volume of the white matter Susceptibility-weighted imaging: Number of cerebral microbleeds |
day 30 & day 180 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02551003 -
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT02683915 -
Reno-protective Effect of Brain Cooling in Newborn With Hypoxia
|
||
Recruiting |
NCT01962233 -
Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Hypoxic Ischemic Encephalopathy
|
Phase 1 | |
Completed |
NCT01471015 -
Darbe Administration in Newborns Undergoing Cooling for Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01683383 -
California Transport Cooling Trial
|
N/A | |
Completed |
NCT01481207 -
Magnetic Resonance Imaging and Spectroscopy Biomarkers of Neonatal Hypoxic Ischemic Encephalopathy
|
||
Completed |
NCT01649648 -
Autologous Cord Blood Cells for Brain Injury in Term Newborns
|
Phase 1 | |
Withdrawn |
NCT00993564 -
Magnetic Resonance Imaging (MRI) Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy (HIE)
|
N/A | |
Completed |
NCT00945789 -
Erythropoietin in Infants With Hypoxic Ischemic Encephalopathy (HIE)
|
Phase 1/Phase 2 | |
Completed |
NCT00097097 -
Neonatal Resuscitation in Zambia
|
Phase 3 | |
Recruiting |
NCT02621944 -
Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia
|
Early Phase 1 | |
Not yet recruiting |
NCT02605018 -
Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01128673 -
MRI Thermal Imaging of Infants Undergoing Cooling for Hypoxic Ischemic Encephalopathy(HIE)
|
N/A | |
Completed |
NCT01732146 -
Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy
|
Phase 3 | |
Completed |
NCT02349672 -
Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (Control Levels)
|
||
Completed |
NCT02826941 -
Moderate Hypothermia in Neonatal Hypoxic Ischemic Encephalopathy
|
Phase 2 | |
Active, not recruiting |
NCT01138176 -
Whole Body Cooling Using Phase Changing Material
|
Phase 1/Phase 2 | |
Terminated |
NCT01765218 -
Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01241019 -
Safety and Efficacy of Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia
|
Phase 2 | |
Completed |
NCT00620711 -
Pilot Study of Head Cooling in Preterm Infants With Hypoxic Ischemic Encephalopathy
|
Phase 1 |